FGFR1 and hepatocellular carcinoma: Altogether, our results suggested that DJ-1/FGFR-1 signaling pathway contribute to sorafenib resistance in HCC, and downregulation of DJ-1/FGFR1 signaling might be a promising strategy to improve the curative effect of sorafenib, especially in those patients with high expression of DJ-1.